AnaptysBio, Inc. is a biotechnology firm currently in the clinical development phase, dedicated to pioneering novel therapeutic agents aimed at treating inflammatory conditions and immuno-oncological diseases. The company's portfolio features several promising drug candidates. These include Imsidolimab, an antibody designed to block the interleukin-36 receptor (IL-36R), targeting diverse skin-related inflammatory disorders. Another key program is Rosnilimab, an anti-PD-1 agonist antibody, which works by enhancing PD-1 signaling to mitigate human inflammatory diseases driven by T-cells. Furthermore, ANB032, an anti-BTLA modulator antibody, addresses human inflammatory conditions linked to imbalances in lymphoid and myeloid immune cell function. Beyond these core assets, AnaptysBio is actively advancing numerous other antibody programs, moving them through preclinical and clinical development phases, often in partnership with other entities. Its strategic alliances include collaboration and licensing agreements with pharmaceutical giants GlaxoSmithKline, Inc. and Bristol-Myers Squibb. Additionally, the firm holds licensing agreements with United Kingdom Research and Innovation and Millipore Corporation. Established in 2005, the company originally operated under the name Anaptys Biosciences, Inc., before rebranding to AnaptysBio, Inc. in July 2006. Its headquarters are situated in San Diego, California.
